Marketing: Page 2
-
CMS approves Louisiana's 'Netflix model' using Gilead hepatitis C drugs
The subscription model will go into effect Monday, and a similar plan by Washington state is also expected to start next week.
By Rebecca Pifer • June 26, 2019 -
Samsung Bioepis CEO urges patience as US biosimilar market lags
"Market shaping takes time," the head of the Korean drugmaker told BioPharma Dive, as a few experts call to give up on the copycat biologics altogether.
By Ned Pagliarulo • June 26, 2019 -
ColumnPharmacquired: Is $11B enough to secure Sanofi's spot in hemophilia?
Gene therapies and other long-acting treatments are threatening to outdate the drugs Sanofi got from its Bioverativ deal.
By Jacob Bell • June 19, 2019 -
Upadacitinib a plus for AbbVie in rheumatoid arthritis, doc survey says
A Piper Jaffray survey of physicians suggests the new drug won't cannibalize Humira, but instead take market share from Olumiant and Xeljanz.
By Jonathan Gardner • June 14, 2019 -
Allergan reportedly hires Spark Foundry as US advertising agency
The new media agency will come on board as Allergan attempts to mount a turnaround, facing discontent from investors.
By Kristin Jensen • June 12, 2019 -
Influential task force urges payers to cover PrEP for HIV
The recommendation from the U.S. Preventive Services Task Force could expand access to Gilead's Truvada, which has come under scrutiny for its cost.
By Samantha Liss • June 12, 2019 -
SponsoredHow pharma can drive value and embrace change in an evolving marketplace
Pharma sales organizations need to adapt to today's evolving healthcare marketplace.
-
Novo Nordisk goes for broke on semaglutide heart data
The diabetes giant is asking the FDA for permission to market cardiovascular claims before a long-term outcomes study is complete.
By Jonathan Gardner • June 11, 2019 -
Judge, CVS witness clash on merger settlement, July hearing set
Federal Judge Richard Leon told lawyers they might want to cancel their summer vacation plans as he voiced concern about the leverage the merged health giant will wield in the marketplace.
By Dana Elfin • June 06, 2019 -
Mitsubishi pulls EU application for ALS drug, citing 'unwarranted' data request
Regulators had concerns that data from a key study that has helped Radicava in other markets isn't strong enough to warrant approval in the bloc.
By Jacob Bell • May 31, 2019 -
Seniors' out-of-pocket spending on cancer drugs climbs higher
Despite efforts to limit Medicare Part D beneficiaries' financial exposure to high-cost drugs, price increases have wiped out some of the expected savings.
By Samantha Liss • May 29, 2019 -
Gilead C-suite shifts again with chief commercial officer appointment
Bristol-Myers Squibb veteran Johanna Mercier will fill the position in July, while Laura Hamill, who joined Gilead's top ranks last year, will be leaving.
By Jacob Bell • May 29, 2019 -
Teva settles for $85M in Oklahoma opioid lawsuit
Yet a looming question for the Israeli pharmaceutical giant, as well as other drugmakers, is whether more states will follow in suing over the opioid crisis.
By Jacob Bell • May 28, 2019 -
Novartis gene therapy approved, but will come at cost of more than $2M
Zolgensma is designed to be a cure for spinal muscular atrophy, but its steep price will pose difficulties for a system designed for chronic therapy rather than one-time treatments.
By Ned Pagliarulo • UPDATED: May 24, 2019 at 2:03 p.m. -
ICER sees current DMD therapies as too pricey, but notes data limitations
Though evidence supporting Sarepta's eteplirsen and golodirsen and PTC's deflazacort "remains sparse," ICER expects all three drugs wouldn't hit certain cost-effectiveness thresholds.
By Jacob Bell • May 23, 2019 -
Private payers cover more than 40% of drug costs
Patients pay 14% of overall retail drug spend in the U.S. in the form of out-of-pocket costs, according to a new analysis from the Kaiser Family Foundation.
By Rebecca Pifer • May 21, 2019 -
ICER seeks to make drug price research more accessible
Pharmas and payers use ICER's work to inform their approach on pricing and coverage, making the group a key voice in the debate over drug value.
By Ned Pagliarulo • May 20, 2019 -
The NASH dash runs into some early hurdles
In a trio of articles, BioPharma Dive explored the key problems the NASH field faces and what's being done to solve them.
By Jacob Bell • May 17, 2019 -
Deep DiveNo one knows the size of the NASH market
Industry is still using a broad estimate for the NASH population, which has led to very different views on the size of the potential market opportunity.
By Jacob Bell • May 16, 2019 -
Deep DiveOn the path to patients, NASH drugs may hit a payer roadblock
Wall Street estimates and clinical data suggest the earliest NASH drugs could come with limited efficacy but high price tags. Healthcare providers fear that won't sit well with payers.
By Jacob Bell • May 15, 2019 -
Deep DiveWill a big needle burst the NASH bubble?
With less invasive tests still a few years off, doctors worry liver biopsies will limit access to the initial wave of NASH drugs — if any make it to market.
By Jacob Bell • May 14, 2019 -
Gilead donates Truvada for PrEP to CDC, with mixed reactions
While the donation will make the preventive treatment available to uninsured Americans, it doesn't lower the cost for others.
By Andrew Dunn • May 10, 2019 -
Nearing gene therapy launch, Bluebird cautions a slower start
Zynteglo, Bluebird's experimental therapy for beta-thalassemia, could soon be cleared in Europe. Reworking payment models to adjust will take time.
By Ned Pagliarulo • May 09, 2019 -
Drugmakers will soon be required to disclose prices in TV ads
Forcing pharma's hand, the Trump administration finalized a proposal requiring list prices in DTC advertising, inviting a possible legal challenge from industry.
By Ned Pagliarulo • May 08, 2019 -
Catalyst dives as FDA approves rival's rare disease drug
Jacobus Pharmaceutical's Ruzurgi is cleared for a different age range than Catalyst's Firdapse, yet investors appear concerned about off-label use eroding the latter's business.
By Jacob Bell • May 07, 2019
Previous
